Estradiol Insert
NDC Package 53746-226-21

11-digit billing NDC: 53746022621

Package Information

Estradiol inserts is estradiol is contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.3)].Breast cancer or history of breast cancer [see Warnings and Precautions (5.3)].Estrogen-dependent neoplasia [see Warnings and Precautions (5.3)].Active DVT, PE, or history of these conditions [see Warnings and Precautions (5.2)].Active arterial thromboembolic disease (for example, stroke or MI), or a history of these conditions [see Warnings and Precautions (5.2)].Known anaphylactic reaction, or angioedema, or hypersensitivity to estradiol [see Warnings and Precautions (5.16)].Hepatic impairment or disease.Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders. This formulation utilizes a insert delivery system. Marketed by Amneal Pharmaceuticals Of New York Llc, this product is identified by NDC 53746-226 and is authorized under FDA application ANDA205256.

Identification & Billing

NDC Package Code
53746-226-21
Package Description
8 APPLICATOR in 1 CARTON / 1 INSERT in 1 APPLICATOR
Product Code
11-Digit Billing Format
53746022621
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Estradiol
Non-Proprietary Name
Estradiol
Substance Name
Estradiol
Dosage Form
Insert - A specially formulated and shaped non-encapsulated solid preparation intended to be placed into a non-rectal orifice of the body, where drug is released, generally for localized effects.
Administration Route
Vaginal - Administration into the vagina.
Active Ingredient(s)
Usage Information
Estradiol is contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.3)].Breast cancer or history of breast cancer [see Warnings and Precautions (5.3)].Estrogen-dependent neoplasia [see Warnings and Precautions (5.3)].Active DVT, PE, or history of these conditions [see Warnings and Precautions (5.2)].Active arterial thromboembolic disease (for example, stroke or MI), or a history of these conditions [see Warnings and Precautions (5.2)].Known anaphylactic reaction, or angioedema, or hypersensitivity to estradiol [see Warnings and Precautions (5.16)].Hepatic impairment or disease.Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.

Regulatory & Marketing

Labeler Name
Amneal Pharmaceuticals Of New York Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA205256
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-07-2015
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (53746-226). Click a package code to view its specific billing and regulatory data.

18 APPLICATOR in 1 CARTON / 1 INSERT in 1 APPLICATOR

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 53746-226-21 identifies a specific commercial package of 8 applicator in 1 carton / 1 insert in 1 applicator of Estradiol, a human prescription drug labeled by Amneal Pharmaceuticals Of New York Llc. This insert is formulated for vaginal use and contains estradiol as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amneal Pharmaceuticals Of New York Llc on June 07, 2015. The current certification is valid through December 31, 2027.

How is this Amneal Pharmaceuticals Of New York Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 53746022621. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
53746-226-21
11-Digit CMS (5-4-2)
53746-0226-21

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.